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Abstract
Aims/hypothesis Accurate prevalence estimates for gestation-
al diabetes mellitus (GDM) among pregnant women in
Europe are lacking owing to the use of a multitude of diag-
nostic criteria and screening strategies in both high-risk wom-
en and the general pregnant population. Our aims were to
report important risk factors for GDM development and cal-
culate the prevalence of GDM in a cohort of women with BMI
≥29 kg/m2 across 11 centres in Europe using the International
Association of the Diabetes and Pregnancy Study Groups
(IADPSG)/WHO 2013 diagnostic criteria.
Methods Pregnant women (n = 1023, 86.3% European eth-
nicity) with a BMI ≥29.0 kg/m2 enrolled into the Vitamin D
and Lifestyle Intervention for GDM Prevention (DALI) pilot,
lifestyle and vitamin D studies of this pan-European
multicentre trial, attended for an OGTT during pregnancy.
Demographic, anthropometric and metabolic data were col-
lected at enrolment and throughout pregnancy. GDM was di-
agnosed using IADPSG/WHO 2013 criteria. GDM treatment
followed local policies.
Results The number of women recruited per country ranged
from 80 to 217, and the dropout rate was 7.1%. Overall, 39%
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of women developed GDM during pregnancy, with no signif-
icant differences in prevalence across countries. The preva-
lence of GDM was high (24%; 242/1023) in early pregnancy.
Despite interventions used in the DALI study, a further 14%
(94/672) had developed GDM when tested at mid gestation
(24–28 weeks) and 13% (59/476) of the remaining cohort at
late gestation (35–37 weeks). Demographics and lifestyle fac-
tors were similar at baseline between women with GDM and
those who maintained normal glucose tolerance. Previous
GDM (16.5% vs 7.9%, p = 0.002), congenital malformations
(6.4% vs 3.3%, p = 0.045) and a baby with macrosomia
(31.4% vs 17.9%, p = 0.001) were reported more frequently
in those who developed GDM. Significant anthropometric
and metabolic differences were already present in early preg-
nancy between women who developed GDM and those who
did not.
Conclusions/interpretation The prevalence of GDM diag-
nosed by the IADPSG/WHO 2013 GDM criteria in
European pregnant women with a BMI ≥29.0 kg/m2 is sub-
stantial, and poses a significant health burden to these preg-
nancies and to the future health of the mother and her off-
spring. Uniform criteria for GDM diagnosis, supported by
robust evidence for the benefits of treatment, are urgently
needed to guide modern GDM screening and treatment
strategies.
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DALI Vitamin D and Lifestyle Intervention for
Gestational Diabetes Mellitus Prevention study
EBCOG European Board and College of Obstetrics and
Gynaecology
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IADPSG International Association of the Diabetes and
Pregnancy Study Groups
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Introduction
Gestational diabetes mellitus (GDM) is defined as carbohy-
drate intolerance resulting in hyperglycaemia of variable se-
verity with onset or first recognition during pregnancy, ex-
cluding those with diabetes in pregnancy likely to represent
overt diabetes mellitus [1]. Women with GDM are more likely
to suffer pregnancy complications, and the diagnosis is asso-
ciated with both immediate and long-term adverse conse-
quences for their offspring [2, 3]. Furthermore, studies inves-
tigating postnatal maternal glucose function have shown the
prevalence of type 2 diabetes to be as high as 38% in the first
year postpartum following GDM, and as high as 60% in wom-
en followed for up to 16 years postpartum [4–6].
The reported prevalence of GDM in Europe varies consid-
erably, and in certain populations is reported to occur in more
than 20% of pregnancies [7, 8]. Unfortunately, accurate prev-
alence estimates in Europe are lacking due to highly inconsis-
tent screening and diagnostic criteria both in high-risk women
and the general pregnant population [9]. This makes pan-
European surveys of GDM very difficult and limits the effects
of large-scale GDM prevention and treatment strategies. In
2010, the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) developed a consensus
statement for a new strategy to diagnose GDM [3]. The cho-
sen cut-off point for glucose on a 75 g OGTTconveyed an OR
for adverse outcomes of ≥1.75 compared with women with
mean glucose levels at 24–28 weeks in the Hyperglycemia
and Neonatal Outcomes study [3, 10]. In 2013, both the
WHO and the Endocrine Society revised their guidelines
and now advise that the IADPSG criteria should be used for
the diagnosis of GDM [1, 11]. The International Federation of
Gynecology and Obstetrics also supports this approach [12].
Recently, the IADPSG has indicated that the criteria are not
for use in early pregnancy [13], but have not provided criteria
for up to 24 weeks’ gestation.
The aim of this study was to use information collected
during the Vitamin D and Lifestyle Intervention for
Gestational Diabetes Mellitus Prevention (DALI) trial to de-
termine risk factors for GDM development and examine the
prevalence of GDM in pregnancy among high-risk women
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with a prepregnancy BMI ≥29 kg/m2 across 11 centres in
Europe using the IADPSG/WHO 2013 diagnostic thresholds.
Methods
The DALI trial was a prospective, multicentre RCT that com-
pared different approaches for preventing GDM progression
in overweight/obese (BMI ≥29 kg/m2) pregnant women re-
cruited prior to 20 weeks’ gestation [7, 14, 15]. A pilot study
was followed by a larger study containing two arms: the life-
style study and the vitamin D study. While the results of the
pilot and lifestyle study are available [14, 15], we await pub-
lication of the vitamin D study results. The presented study
population consists of women from the pilot, lifestyle and
vitamin D cohorts [14, 15]. The DALI study enrolled women
from 11 centres in nine European countries, representing
north, south, east and west areas of Europe (UK, Ireland,
Austria, the Netherlands, Belgium, Denmark [two sites],
Italy [two sites], Spain, Poland). Each local research ethics
committee approved the study and written informed consent
was obtained from all participants. The study was performed
in accordance with the principles of the Declaration of Helsinki
and is registered in the ISRCTN registry (ISRCTN70595832).
Participant involvement Representatives of the target group
were interviewed in the developmental stage of the DALI trial
about their preferences regarding intervention content, modal-
ity, frequency and location. These representatives were not
involved in the actual conduct of the study, but participants
provided feedback on the burden of the intervention and their
experiences with the study in general, as part of a process
evaluation. Patient organisations have been actively involved
in disseminating the results to the lay public.
Participants The main inclusion criteria were: age ≥18 years,
singleton pregnancy up to and including 19 + 6 weeks of
gestation, BMI ≥29 kg/m2 before pregnancy (based on RCT
feasibility following a review of European obesity prevalence)
and ability to give informed consent. Exclusion criteria includ-
ed pre-existing diabetes, the need for a complex diet, inability
to walk ≥100 m safely and the presence of a significant chron-
ic medical condition or psychiatric disease. Consecutive
consenting women undertook a 75 g OGTT at <20 weeks’
gestation, with GDM diagnosed from venous samples using
locally available laboratory methods according to the
IADPSG/WHO 2013 criteria (fasting plasma glucose
≥5.1 mmol/l, 1 h plasma glucose ≥10.0 mmol/l or 2 h plasma
glucose ≥8.5 mmol/l) (IADPSG). Women diagnosed with
GDM at baseline were excluded from the RCT (lifestyle
and/or vitamin D studies). The remaining participants were
retested at mid gestation (24–28 weeks) and, if GDM was
not diagnosed, were retested again at late gestation (35–
37 weeks) with a further 75 g OGTT using IADPSG/WHO
2013 criteria. Recruitment was conducted between January
2012 and February 2014.
Assessments Information regarding demographic, anthropo-
metric and metabolic factors was obtained from all women at
enrolment through anthropometric and metabolic measure-
ments and by completion of questionnaires [14]. Both neck
and waist circumferences were included in the anthropometric
assessments, as prior research has demonstrated a relationship
between these measurements and glucose intolerance [16, 17].
A 75 g OGTTwas performed, with blood samples for glucose
and insulin taken at fasting and at 60 and 120 min after glu-
cose ingestion. HOMA-IR was calculated using glucose and
insulin values (fasting plasma glucose level [mmol/l] × fasting
insulin level [pmol/l]/135) [18].
Data analyses Data were entered into a bespoke web-based
electronic database. Descriptive data analysis was performed
for all variables. Continuous variables are summarised by
mean ± SD and categorical variables by counts and percent-
ages. Comparisons between GDM and normal glucose toler-
ant (NGT) women were performed using t tests and/or
ANOVA for continuous data and χ2 tests for binary data.
For non-normally distributed data, non-parametric tests were
used to compare ranks between groups. Multivariate logistic
regression models were applied to identify risk factors for
GDM diagnosis at any time point adjusting for potential con-
founders. Variables significant in univariate analysis, as well
as those previously identified as risk factors in the literature,
were entered into the multivariate model. To avoid collinear-
ity, highly correlated factors were entered in separate models
(e.g. BMI, weight, neck and waist circumference). The risk
factor with the highest OR was retained in these instances.
Factors (at baseline) included age, weight, BMI, neck/waist
circumference, marital status, education, parity, employment,
alcohol consumption, smoking, (family) history of GDM and
previous pregnancy risk factors (congenital malformation,
macrosomic baby [>4 kg], previous pregnancy loss, polycys-
tic ovary syndrome [PCOS], chronic hypertension). Statistical
analysis was performed using SPSS version 21.0 (SPSS,
Chicago, IL, USA). A two-sided p value <0.05 was consid-
ered statistically significant. No imputations were made for
missing data.
Results
DALI enrolment Enrolment occurred across 11 sites in nine
European countries. A total of 3544 women were screened
and 1023 (28.9%) were enrolled (pilot, lifestyle and vitamin
D trials), of whom 73 women (7.1%) dropped out or were lost
to follow-up across all sites. Enrolment rates (defined as the
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percentage of eligible women enrolled per site) among coun-
tries ranged from 7.8% to 21.2% (average 11%), giving a wide
spread across the European populations (Table 1).
Prevalence of GDM Table 2 outlines the GDM prevalence by
period of gestation and country. A total of 395/1023 women
were diagnosed with GDM at some time during pregnancy:
242 (61.3%) in early pregnancy, 94 (23.8%) at mid gestation
and 59 (14.9%) at late gestation. There was a high prevalence
of GDM in early pregnancy (<20 weeks’ gestation), with 242
women (24%) from the overall population of 1023 diagnosed
at this point. Five of these women met the criteria for overt
diabetes in pregnancy. Of the 242 women diagnosed in early
pregnancy, 190 (78.5%) met the diagnostic criteria based on
fasting glucose alone (≥5.1 mmol/l). Five women of Asian
ethnicity were diagnosed in early pregnancy and all five were
diagnosed based on fasting glucose, with two of these women
exceeding the glucose cut-off at all three time points. Women
diagnosed in early pregnancy were not enrolled in the DALI
RCT. There was a spread in the prevalence of GDM in early
pregnancy, from a low of 10–11% in the UK and Ireland to a
high of 43% in Denmark. A total of 672 women were retested
at mid gestation (24–26 weeks), and 94 (14%) had developed
GDM despite the interventions of the trial. Once again, there
was a spread in prevalence from a low of 8% in Ireland to a
high of 21% in Italy. Finally, 476 womenwhowere previously
categorised as having NGT (without GDM at the OGTT at
24–26 weeks) completed the final OGTT at 35–37 weeks’
gestation, of whom 59 (13%) had developed GDM despite
diet and lifestyle interventions. There was a spread in preva-
lence from a low of 9% in Italy to a high of 16% in Belgium.
Overall, 395 (39%) women fulfilled the IADPSG/WHO 2013
criteria for GDM at any point within the trials. The lowest
overall prevalence was in the UK (24%) and the highest prev-
alence was in Denmark (52%).
Demographic and lifestyle factors Table 3 outlines the de-
mographic and lifestyle factors at baseline for all women
enrolled in the DALI RCT according to glucose tolerance
status (GDM at any time vs NGT). There was no significant
difference in ethnicity between those who maintained NGT
and those who developed GDM during the trial. More than
50% of participants reported having a high (university-
equivalent) level of education, reflective of the university cit-
ies in which recruitment occurred. The percentage of women
with a low level of education was similar in those with NGT
and GDM at 12.0% and 12.8%, respectively. Overall, 5.2% of
women reported consuming alcohol during pregnancy. One
third of fathers (33.8%) were active smokers, double the rate
reported by mothers (16.2%), with no difference in active
smoking between women with NGT and GDM. Nulliparous
women accounted for 50.3% of the total cohort.
Maternal GDM risk factors Maternal risk factors for
GDM development at enrolment are displayed in
Table 4. There were no differences between women
with GDM at any time and those with NGT with re-
spect to a history of diabetes in a first-degree relative,
PCOS, reported chronic hypertension or a reported pre-
vious pregnancy loss. More women with GDM than
NGT reported a previous history of GDM (16.5% vs
7.9%, p = 0.002), congenital malformations (6.4% vs
3.3%, p = 0.045) and a previous macrosomic baby
(31.4% vs 17.9%, p = 0.001).
Anthropometric/metabolic characteristics prepregnancy
and at first assessment
Table 5 shows anthropometric and metabolic measure-
ments among women with NGT and those with early
and mid/late pregnancy GDM. Significant differences
were observed between women with NGT and those
with GDM. Reported mean prepregnancy and enrolment
weight and BMI were significantly greater in women
with GDM in early pregnancy. Mean waist circumfer-
ence was significantly different among those with NGT
Table 1 Enrolment of pregnant
women in the DALI pilot, life-
style and vitamin D studies by
country
Country Number enrolled Percentage of total trial population
Denmark (two sites) 217 21.2
UK 125 12.2
Italy (two sites) 116 11.3
Austria 110 10.8
Belgium 101 9.9
Spain 99 9.7
Poland 91 8.9
Ireland 84 8.2
Netherlands 80 7.8
TOTAL 1023 100
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(107.3 cm), those with early GDM (114.4 cm) and
those with GDM in mid or late pregnancy (107.1 cm)
(p = 0.009). Significant differences were also noted
among the groups in terms of systolic BP, diastolic BP
and heart rate, with higher measurements observed for
those women with GDM in early pregnancy. As expect-
ed, women with GDM in early pregnancy had higher
fasting, 1 h and 2 h glucose levels, but these levels
were also significantly higher in women who went on
to develop GDM later compared with women with
NGT. HOMA-IR at first assessment was significantly
higher in those with early vs mid/late GDM, and those
with NGT had the lowest level (4.5, 3.6 and 3.0, re-
spectively; p < 0.001).
Risk of GDM development Table 6 outlines the results of a
multivariate logistic regression analysis to evaluate the OR of
GDM development. Independent risk factors for GDM devel-
opment were nulliparity (OR 1.6, 95% CI 1.0, 2.5), neck cir-
cumference at initial visit (OR 1.1, 95% CI 1.0, 1.2), GDM in
a previous pregnancy (OR 2.3, 95% CI 1.3, 4.0) and a previ-
ous macrosomic baby (OR 1.7, 95% CI 1.1, 2.6).
Pregnancy outcomes according to glucose tolerance
Table 7 shows pregnancy outcomes for all women enrolled
in the DALI study vs those with a diagnosis of GDM at mid or
late pregnancy (those with early GDM were excluded from
enrolment) or NGT. No significant differences were found.
Table 2 GDM prevalence ac-
cording to gestation period and
country
Country Participants enrolled,
n
Participants with GDM, n (%) GDM total, n
(%)
Early
pregnancy
Mid
pregnancy
Late
pregnancy
Denmark 217 93/217 (43) 11/106 (10) 8/77 (10) 112/217 (52)
Belgium 101 21/101 (21) 12/75 (16) 10/61 (16) 43/101 (43)
Spain 99 25/99 (25) 10/65 (15) 6/46 (13) 41/99 (41)
Netherlands 80 27/80 (34) 4/44 (9) 1/18 (5) 32/81 (41)
Poland 91 17/91 (19) 12/68 (18) 7/47 (15) 36/91 (40)
Austria 110 22/110 (20) 12/72 (17) 6/45 (13) 40/110 (36)
Italy 116 16/116 (14) 18/85 (21) 5/54 (9) 39/116 (34)
Ireland 84 9/84 (11) 5/63 (8) 7/47 (15) 21/84 (25)
UK 125 12/125 (10) 10/94 (11) 9/74 (12) 31/125 (24)
TOTAL 1023 242/1023 (24) 94/672 (14) 59/476 (13) 395/1023 (39)
Table 3 Demographic/lifestyle
factors of participants at
enrolment
Variable (%) All women NGT GDMa p valueb
Ethnicity
European 86.3 86.4 86.2 NS
Non-European 13.7 13.6 13.8 NS
Education
High 55.2 56.9 52.4 NS
Medium 32.5 31.1 34.3 NS
Low 12.3 12.0 12.8 NS
Living with a partner 93.4 93.8 91.8 NS
Employment status
Working 77.0 77.1 76.8 NS
Not working 14.3 13.8 15.0 NS
Home duties 8.7 9.1 8.2 NS
Current maternal alcohol consumption 5.2 6.1 3.8 NS
Current maternal smoking 16.2 16.7 15.4 NS
Current paternal smoking 33.8 34.6 32.6 NS
Nulliparous 50.3 48.7 52.9 NS
aAt any time during pregnancy
bWomen with NGT vs GDM
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Discussion
Using IADPSG/WHO 2013 criteria, we found an overall GDM
prevalence of 39%, across early, mid and late gestation among
overweight/obese women who were evaluated for inclusion in
the DALI trial. Participants were well distributed across 11
European centres, with the largest cohort (21.2%) attending
two sites in Denmark. These data from the DALI trial allow for
a meaningful interpretation of the European prevalence of GDM,
as identical screening was used in 11 centres across nine
European countries, using the IADPSG/WHO 2013 criteria. A
substantial proportion of women with GDM were identified in
early pregnancy (24%), with 14% and 13% ofwomen diagnosed
at mid and late pregnancy, respectively. The prevalence of GDM
varied across countries, ranging from 24% in the UK to 52% in
Denmark. These findings are in contrast to prior prevalence data
that included women across all BMI categories and reported an
overall prevalence of 2–6%, with a lower prevalence towards the
northern Atlantic seaboard of Europe compared with the south-
ern Mediterranean seaboard [8]. This variance is probably due to
a lack of screening uniformity in the aforementioned study, lower
glucose cut-off points in the IADPSG/WHO 2013 criteria
Table 4 Maternal risk factors for
GDM development Variable (%) All women NGT GDM
a p valueb
Diabetes in a first-degree relative 24.6 23.7 27.7 NS
PCOS 10.4 10.3 10.7 NS
Chronic hypertension 13.0 12.8 13.7 NS
Previous GDMc 9.8 7.9 16.5 0.002
Previous baby with a congenital malformationc 4.0 3.3 6.4 0.045
Previous macrosomic babyc 21.0 17.9 31.4 0.001
Previous pregnancy lossc 11.1 10.2 14.1 NS
aAt any time during pregnancy
bWomen with NGT vs GDM
c In women with a previous pregnancy
Table 5 Anthropometric/meta-
bolic factors prepregnancy and in
early pregnancy according to
glucose tolerance
Variable NGT GDM early
pregnancy
GDM mid/late
pregnancy
p
valuea
p
valueb
Age at enrolment (years) 31.9 ± 5.4 32.7 ± 5.1 32.0 ± 5.0 NS NS
Height at enrolment (cm) 165.7 ± 6.7 165.5 ± 6.1 165.0 ± 7.4 NS NS
Prepregnancy weight (kg) 92.8 ± 13.5 96.8 ± 16.1 91.0 ± 14.9 <0.001 <0.001
Prepregnancy BMI (kg/m2) 33.7 ± 4.2 35.3 ± 5.4 33.4 ± 4.7 <0.001 <0.001
Weight at enrolment (kg) 94.8 ± 13.5 99.3 ± 17.1 93.5 ± 14.7 <0.001 <0.001
BMI at enrolment (kg/m2) 34.5 ± 4.2 36.2 ± 5.6 34.2 ± 4.4 <0.001 <0.001
Waist circumference at
enrolment (cm)
107.3 ± 10.1 114.4 ± 60.9 107.1 ± 10.1 0.009 NS
Neck circumference at
enrolment (cm)
36.3 ± 2.1 37.4 ± 4.9 36.3 ± 2.2 <0.001 0.008
Systolic BP at enrolment
(mmHg)
116.4 ± 11.1 118.5 ± 10.1 115.9 ± 10.8 0.03 0.019
Diastolic BP (mmHg) 72.8 ± 8.5 75.1 ± 8.5 73.0 ± 11.8 0.003 0.036c
Heart rate at enrolment
(beats/min)
79 ± 10.2 82 ± 10.6 81 ± 9.3 0.001 NS
Fasting glucose in early
pregnancy (mmol/l)
4.5 ± 0.3 5.2 ± 0.5 4.6 ± 0.3 <0.001 <0.001
1 h glucose in early pregnancy
(mmol/l)
6.5 ± 1.4 8.9 ± 2.0 7.5 ± 1.4 <0.001 <0.001
2 h glucose in early pregnancy
(mmol/l)
5.7 ± 1.1 7.3 ± 1.7 6.2 ± 1.1 <0.001 <0.001
HOMA-IR 3.0 ± 2.6 4.5 ± 2.7 3.6 ± 3.6 <0.001 0.007
Data are means ± SD
aComparison across the three groups
bGDM in early pregnancy vs GDM in mid/late pregnancy
cNS when applying Bonferroni adjustment for multiple comparisons
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compared with other guidelines and the inclusion of only women
with a BMI ≥29 kg/m2 in the current study.
Within this group of women at high risk for GDM, there
was no variation in demographic or lifestyle factors according
to glucose tolerance, and certain previously reported risk fac-
tors (prior GDM, prior macrosomia) were associated with
GDM in logistic regression analysis. However, other well-
established risk factors for GDM, such as a diagnosis of
PCOS and diabetes in a first-degree relative, were not signif-
icant: this might be due to their mediation by the overwhelm-
ing risk effect of obesity and might be different in a population
of women with a wider range in prepregnancy BMIs. While
there were variations in GDM prevalence among countries,
we did not include country as a variable in our analyses, as a
categorical variable with nine levels would cost degrees of
freedom and our sample size was insufficiently powered for
such an analysis. Overall, however, the significant risk of
GDM observed among these overweight/obese women is of
concern, given the global rise in obesity and the knowledge
that both obesity and GDM are independently associated with
adverse maternal–fetal outcomes [10, 19]. Furthermore, 70%
of obese women with GDM have been reported to develop
type 2 diabetes within 15 years of delivery, compared with
30% of lean women with GDM [20, 21]. It is evident that
effective policies to reduce obesity levels are necessary, and
that this may result in both clinical and economic benefits
[22]. Indeed, an initial step may be to ensure universal BMI
screening for women of reproductive age. Then, clinicians
may be more likely to assist with weight loss and provide
appropriate care to identify and reduce secondary complica-
tions of increasing BMI [23, 24].
Among women with a BMI ≥29.0 kg/m2 in the current
study, those with GDM in early pregnancy had a significantly
higher weight and BMI than women with NGTand those with
GDM in mid/late pregnancy. It is an interesting observation
that these differences were limited to women with early GDM,
while women with GDM in mid/late pregnancy only were not
significantly different from those with NGT in terms of weight
and BMI. Similar findings were observed for neck circumfer-
ence and systolic and diastolic BP. This is useful clinical in-
formation and could be used in a ‘risk score’ for early GDM,
although we would recommend screening all women with a
BMI ≥29.0 kg/m2. The use of neck circumference is a novel
measure andmay overcome inaccuracies associatedwithmea-
suring waist circumference [25]. After excluding women with
early GDM,women whowent on to develop GDM inmid/late
pregnancy in the current study also had elevated glucose
levels at baseline compared with those who continued to have
NGT. This trend was also evident when examining measures
of insulin resistance. While there are limitations to indices
such as HOMA-IR, such as racial differences in mixed popu-
lations, they act as a reasonable surrogate for the gold standard
euglycaemic–hyperinsulinaemic clamp [16, 26]. In this study,
women with GDM in early pregnancy had significantly higher
HOMA-IR values than those with GDM in later pregnancy or
those with NGT, as has been previously reported [27]. These
findings support prior work characterising women with early-
onset GDM as having higher levels of insulin resistance and
those with GDM in later pregnancy as being more similar to
Table 6 Multivariate logistic regression analysis evaluating the risk of
GDM (yes/no) at any stage of gestation
Variable OR 95% CI p value
Nulliparous 1.6 1.0, 2.5 0.032
Neck circumference at initial evaluation (cm)a 1.1 1.0, 1.2 0.011
GDM in previous pregnancy 2.3 1.3, 4.0 0.004
Previous macrosomic baby 1.7 1.1, 2.6 0.014
a Continuous variable
Table 7 Pregnancy outcomes for
women enrolled in the DALI tri-
als according to glucose status
Variable All women NGT GDMmid/late pregnancya p valueb
Caesarean section 36.2 34.1 40.2 NS
Pre-eclampsia 3.1 2.8 3.8 NS
Pregnancy-induced hypertension 12.2 11.3 14.2 NS
Birthweight ≥4 kg 16.4 15.2 18.5 NS
Birthweight <2.5 kg 3.9 3.4 4.8 NS
Neonatal intensive care unit admission 9.0 9.9 6.6 NS
Gestational age at delivery (weeks) 39.6 ± 5.9 39.5 ± 3.0 39.8 ± 9.6 NS
Birthweight (g) 3468 ± 578 3456 ± 524 3488 ± 657 NS
Birth length (cm) 51.4 ± 3.5 51.4 ± 3.3 51.4 ± 3.8 NS
Data are % or means ± SD
aWomen with early GDM were excluded from the DALI study, and pregnancy outcomes are therefore unavail-
able for this group
bWomen with NGT vs GDM
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women with NGT [28]. Higher BMIs among women with
early-onset GDM are felt to at least partially explain this
phenomenon.
Although screening practices vary, one commonly used
approach is to screen the majority of women for GDM at
24–28 weeks’ gestation, with earlier testing reserved for those
with risk factors [29]. However, almost a quarter of our cohort
was positive for GDM in early pregnancy (<20 weeks’ gesta-
tion). While the diagnostic cut-off values for GDM in early
pregnancy are controversial [9, 13], our findings indicate that
there is some evidence that early screening in obese women
may be warranted. As the majority of these women were cap-
tured using fasting glucose alone, there may be a role for using
this measure rather than completing a full OGTT. Screening is
of particular importance in the presence of the additional risk
factors we found to be independently associated with GDM
development at any stage of gestation. On multivariate analy-
sis, a history of GDM in a previous pregnancy was the stron-
gest independent risk factor identified (OR 2.3). This was
followed by a history of having a macrosomic baby (OR
1.7). Future work should consider the use of large for gesta-
tional age as an alternative risk factor to macrosomia, as the
former can be customised to take into account the specific
population under evaluation. Additional independent risk fac-
tors included nulliparity (OR 1.6) and a larger neck circum-
ference on initial evaluation (OR 1.1).
Women in this study were diagnosed according to the
IADPSG/WHO 2013 criteria [1, 3]. While international prac-
tices vary, this approach adopted by the DALI study is in
keeping with recommendations from the European Board &
College of Obstetrics and Gynaecology and the International
Federations of Gynecology and Obstetrics [9, 30]. Due to a
lower fasting glucose cut-off of 5.1 mmol/l, use of the
IADPSG/WHO 2013 criteria results in an increased preva-
lence of GDM compared with alternative diagnostic criteria;
however, the use of these criteria is supported by data reveal-
ing that women with fasting plasma glucose levels of 5.1–
5.5 mmol/l have an increased risk of adverse outcomes [31].
It is hoped that there will be a move towards uniformity in the
diagnosis of GDM across Europe in the future. This will stim-
ulate research in the field of GDM and allow more women to
receive a timely diagnosis and appropriate treatment for
GDM. It is clear that the criteria for diagnosing GDM in early
pregnancy need urgent resolution, and studies to delineate
these criteria and quantify any benefits from treatment are
urgently required.
Limitations of our findings include the fact that women
were recruited and consented to join an RCT, which may have
resulted in selection bias. In particular, the high rates of wom-
en reporting a previous macrosomic baby suggest that there
may have been increased recruitment in women who were
perceived (or who perceived themselves) to be at higher risk.
The drop out rate of 7.1% compares well with that noted in the
UPBEAT study, a similar multicentre trial involving complex
lifestyle interventions with the aim of reducing GDM inci-
dence [32]. The primary reasons cited for dropping out in
the DALI pilot and lifestyle studies included lack of time
and pregnancy loss [14, 15]. We do not address the optimal
GDM prevention strategy, as women received a variety of
lifestyle modifications and vitamin D therapy during the
DALI trial, and these are reviewed in the DALI pilot and
lifestyle RCT outcomes papers [14, 15]. If the interventions
had an impact on individual women then the prevalence of
GDM in mid to late pregnancy calculated in the current study
may be an underestimate. On the other hand, as discussed in
relation to early pregnancy, use of the IADPSG criteria to
diagnose additional individuals with GDM in late pregnancy
is not validated and the justification for this requires further
study. Finally, once diagnosed with GDM, women were man-
aged according to local practice at each site and this could
have influenced birth outcomes.
Nevertheless, the women in this study were from a wide
spectrum of European countries and the data were carefully
collected, recorded and analysed to give an accurate overview
of GDM patterns in this population. This work fills an impor-
tant gap in the literature and highlights the high prevalence of
GDM associated with obesity in a European population.
In conclusion, the overall prevalence of GDM diagnosed
by the IADPSG/WHO 2013 GDM criteria in European preg-
nant women with a BMI ≥29 kg/m2 participating in the DALI
study was high (39%). We have identified a number of inde-
pendent risk factors for GDM development in this cohort. It is
evident that there is an urgent need for uniform strategies for
screening and diagnosing GDM, along with effective preven-
tive interventions.
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